Patient Satisfaction with Tapinarof Cream 1% Once Daily for Plaque Psoriasis in a Long-Term Extension Trial

Jerry Bagel, MD, 1 Linda Stein Gold, MD, 2 James Del Rosso, DO, 3 Neal Bhatia, MD, 4 Sandy Johnson, MD, 4 Paul Yamada, MD, 4 Angela Y. Moore, MD, 7 Anna M. Tallman, PharmD 4

1Psoriasis Treatment Center of Central New Jersey, East Windsor, NJ, USA; 2Henry Ford Health System, Detroit, MI, USA; 3IUR Dermatology Research/Thomas Dermatology, Las Vegas, NV, USA and Advanced Dermatology & Cutaneous Surgery, Maitland, FL, USA; 4Therapeutics Clinical Research, San Diego, CA, USA; 5Johnson Dermatology, Fort Smith, AR, USA; 6Dermatology Institute & Skin Care Center, Santa Monica, CA, USA; 7Arborcet Dermatology, Arborcet Research Center, Arlington, TX, USA; 8Dermavant Sciences, Inc., Montrose, CA, USA.

BACKGROUND

Patient dissatisfaction with current therapies is an important barrier to optimal care of psoriasis (52% of psoriasis patients have reported dissatisfaction with their treatment) and there is a need for efficacious, tolerable, easy-to-use topical therapies that can be used long term, including on sensitive skin areas.

Objective

Given that patient dissatisfaction with current therapies has a significant impact on disease management, we assessed patient satisfaction using a Patient Satisfaction Questionnaire; here we present the results from PSOARING 3, a long-term, open-label extension trial of tapinarof cream 1% QD.

METHODS

Patient Satisfaction Questionnaire

- Eighty-five percent of patients strongly agreed or agreed with all questions on confidence and satisfaction with the efficacy of tapinarof cream (Figure 3).

- For patients who reported having used other topical drugs to treat psoriasis in the past, 81.7% considered tapinarof to be more effective than prior drugs, and 65.3% considered tapinarof easier to use (Figure 5a).

- For patients who reported having used systemic drugs to treat psoriasis in the past, 55.3% considered tapinarof to be more effective than prior therapies, and 63.8% considered tapinarof to be easier to use (Figure 5b).

- Most patients (67%) also preferred tapinarof because the time spent applying tapinarof was considered to be shorter than with prior therapies (Figure 5c).

RESULTS

Patient Satisfaction Questionnaire

- Ninety-one percent of eligible patients (n=763) completing PSOARING 1 and 2 elected to enroll in PSOARING 3.

- Ninety-one percent of patients consistently reported high satisfaction rates across all parameters, including patients’ satisfaction with tapinarof efficacy, formulation elegance, application ease, impact on daily life, and preference for tapinarof cream versus prior therapies.

Confidence and Satisfaction with the Efficacy of Tapinarof Cream

- Most patients either strongly agreed or agreed with all questions on confidence and satisfaction with the efficacy of tapinarof cream (Figure 3).

- Eighty-five percent felt they could easily manage their psoriasis with tapinarof, and 83% were satisfied with how well tapinarof worked.

- In addition to the 40% of patients who achieved complete disease clearance and the observed remittance effect of 4 months, 62.9% of patients either strongly agreed or agreed that tapinarof cleared their skin and kept psoriasis from coming back.

- Eighty-four percent had confidence in tapinarof, and 84% would recommend tapinarof to other patients with psoriasis.

- Eighty-two percent of patients would use tapinarof again or continue on tapinarof if it was available (Figure 3).

CONCLUSION

Patient satisfaction data from PSOARING 3 demonstrate a consistent and highly positive perception of tapinarof cream 1% QD across all patient relevant parameters, including satisfaction with tapinarof efficacy, formulation elegance, application ease, impact on daily life, and preference for tapinarof cream versus prior therapies.

REFERENCES


ACKNOWLEDGMENTS

Treats were funded by Dermavant Sciences, Inc. and the authors thank the investigators, patients, and their families, and colleagues involved in their conduct. J.B. has received research funds payable to Psoriasis Treatment Center and/or speaking/consultant fees from AbbVie, Amgen, Arcutis Biotherapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Corrona LLC, Dermavant Sciences, Ltd, Derma/UCB, Eli Lilly, Glimark Pharmaceuticals Ltd, Janssen Biotech, Kadmon Corporation, LEO Pharma, Lycera Corp, Menlo Therapeutics, Novartis, Pfizer, Regeneron, Sun Pharma, Taiho Pharmaceutical Industries Ltd, UCB, and Valeant Pharmaceuticals. L.S.G. has served as a consultant and/or has received payment for the development of educational presentations, and/or has received grants from Arcutis, Amgen, Bristol Myers Squibb, Dermavant Sciences, Inc, Eli Lilly, LEO Pharma, Ortho Dermatologic, Pfizer, and UCB Biopharma. J.D.R. is a consultant and research investigator for Dermavant Sciences, Inc. N.B. is a consultant with honorarium and an investigator for Dermavant Sciences, Inc. S.J. is an advisor and/or speaker and/or editor and/or in clinical trials for AbbVie, Aclaris, AFMC, Allergan, Candela Syneron, Cassiopeia, Celgene, Amgen, Chemocentryx, Dermavant Sciences, Inc., Dermira, FanoMix, Gage, Galderma, GSK, Journal of Arkansas Medical Society, LEO, Eli Lilly, National Psoriasis Foundation, Nielsen, Novartis, Praxtal Dermatology, Regeneron, Sanofi Genzyme, Skin Medical, TARGET Therapeutics, and the University of Pennsylvania. P.Y. has served as an investigator and/or speaker and/or consultant for AbbVie, Amgen, Arcutis, BMS, Dermavant, EPI Health, Incyte, Janssen, Lilly, Leo, Novartis, Pfizer, Sun Pharma, and UCB. A.Y.M. has served as an investigator for Dermavant Sciences, Inc. A.M.T. is an employee of Dermavant Sciences Inc., with stock options. Editorial and medical writing support under the guidance of the authors was provided by ApotheCom, UK, and was funded by Dermavant Sciences, Inc. in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med 2015;163:461–464). Contact Dr Bagel at dreamacres1@aol.com with questions or comments.